On November 13, GeneDx Holdings fell 5.53% in Pre-Market Trading, trading at $48.9 per share, with turnover of $3.5349 million.
The clearest catalyst was continued market digestion of cautious guidance issued with the latest quarterly report, despite earnings and revenue both slightly exceeding consensus.
GeneDx Holdings reported adjusted EPS of $0.28 for the September quarter, above the $0.07 consensus, on revenue of $123.1 million versus expectations of $122.9 million. However, Q4 revenue guidance of $135 million was below the $142.6 million consensus, while full-year revenue guidance was maintained at $475 million to $490 million rather than raised. Analyst support remained in place, with Piper Sandler maintaining a Buy and $95 target, but BTIG cut its target to $85 from $90 and Jefferies lowered its target to $80 from $100, reinforcing a more cautious view on the near-term growth pace.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments